Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy.
Authors
Suciu, SEggermont, A
Lorigan, Paul C
Kirkwood, J
Markovic, S
Garbe, C
Cameron, D
Kotapati, S
Chen, T
Wheatley, K
Ives, N
de Schaetzen, G
Efendi, A
Buyse, M
Affiliation
European Organisation for Research and Treatment of Cancer Headquarters, Brussels, BelgiumIssue Date
2018-01-01
Metadata
Show full item recordAbstract
We assessed whether relapse-free survival (RFS; time until recurrence/death) is a valid surrogate for overall survival (OS) among resected stage II-III melanoma patients through a meta-analysis of randomized controlled trials.Citation
Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy. 2018, 110 (1): J Natl Cancer InstJournal
Journal of the National Cancer InstituteDOI
10.1093/jnci/djx133PubMed ID
28922786Type
ArticleLanguage
enISSN
1460-2105ae974a485f413a2113503eed53cd6c53
10.1093/jnci/djx133
Scopus Count
Collections
Related articles
- Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
- Authors: Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A
- Issue date: 2012 Jan
- Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
- Authors: Weber JS, Ascierto PA, Middleton MR, Hennicken D, Zoffoli R, Pieters A, Amadi A, Kupas K, Kotapati S, Moshyk A, Schadendorf D
- Issue date: 2021 Nov
- Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
- Authors: Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U
- Issue date: 2012 Nov 1
- Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
- Authors: Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suciu S, Testori A
- Issue date: 2019 Sep
- Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.
- Authors: Coart E, Suciu S, Squifflet P, Saad ED, Moshyk A, de Schaetzen G, Buyse M, Weber JS, Eggermont A, Kotapati S
- Issue date: 2020 Sep